IMAGES

  1. Clinical Trials

    latest research in prostate cancer

  2. Prostate Cancer Research Study

    latest research in prostate cancer

  3. Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy

    latest research in prostate cancer

  4. By the numbers: Prostate cancer

    latest research in prostate cancer

  5. Prostate Cancer: An Overview (Updated 2022)

    latest research in prostate cancer

  6. (PDF) What’s new in prostate cancer research?

    latest research in prostate cancer

VIDEO

  1. Future of Prostate Cancer: Breakthroughs, Treatments, and Holistic Approaches

  2. Prostate Cancer Breakthrough Urine Test Avoids Unnecessary Biopsies

  3. 10 Must-Eat Foods To shrink Enlarged Prostate & 10 to Avoid"

  4. Genetic Predisposition to Prostate Cancer & Relevance to Targeted Screening

  5. SEPTEMBER IS PROSTATE CANCER AWARENESS MONTH

  6. Prostate Cancer: From Diagnosis to Recovery

COMMENTS

  1. Advances in Prostate Cancer Research - NCI

    Find what's new in prostate cancer research, including current progress in improving biopsies and imaging for diagnosis, and in treating prostate cancer with hormone therapy, immunotherapy, and targeted therapy. Selected NCI-supported programs are also described.

  2. Fifteen-Year Outcomes after Monitoring, Surgery, or ...

    In the United States in 2020, approximately 192,000 men received a diagnosis of prostate cancer and 33,000 died of the disease. 1 Since the U.S. Preventive Services Task Force updated its...

  3. A Promising New Therapy for Advanced Prostate Cancer

    Prostate cancer treatment stands on the brink of a major advance with the development of a new treatment that zeros in on cancer cells to destroy them. The therapy, called 177 Lu-PSMA-617, uses a molecule that selectively seeks out and attaches to a specific protein on the cancer cell surface.

  4. FDA approves new treatment for advanced prostate cancer

    In June, the FDA approved a new treatment for the most advanced type of prostate cancer. Patients who have this condition, which is called metastatic castration-resistant prostate cancer (mCRPC), have few therapeutic options, so the approval helps to fill an urgent need.

  5. The Lancet Commission on prostate cancer: planning for the ...

    Prostate cancer is the most common cancer in men in 112 countries, and accounts for 15% of cancers. In this Commission, we report projections of prostate cancer cases in 2040 on the basis of data for demographic changes worldwide and rising life expectancy.

  6. FDA Approves Relugolix for Advanced Prostate Cancer

    In a large clinical trial, the drug, relugolix (Orgovyx), was shown to be more effective at reducing testosterone levels in men with advanced prostate cancer than another commonly used treatment, leuprolide (Lupron).